Conclusions
HDTs offer a unique treatment strategy to combat Mtb infections, but are
challenged by complex and multiscale interactions between drug, host and
pathogen. Several key mechanisms are of interest to be exploited as HDTs
but are facing challenges in translation towards clinically effective
treatment strategies. The combined use of multiple in vitro and in vivo
experimental infection models can offer a more complete, quantitative
and predictive understanding of drug-host-pathogen interactions. This
should be combined with QSP modelling strategies that integrate data to
enable translation towards patients and to help designing optimal
clinical treatment strategies for HDTs in combination with classical
antibiotics.